Skip to main content

Market Overview

Recap: Veru Q4 Earnings



Shares of Veru (NASDAQ:VERU) moved higher by 4.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 160.00% year over year to $0.03, which beat the estimate of ($0.04).

Revenue of $11,749,000 up by 34.61% year over year, which beat the estimate of $10,630,000.


Veru hasn't issued any earnings guidance for the time being.

Veru hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Dec 09, 2020

Time: 08:00 AM

ET Webcast URL:

Price Action

52-week high: $4.74

Company's 52-week low was at $2.10

Price action over last quarter: Up 26.12%

Company Overview

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.


Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at